ZB-16, a Novel GPR119 Agonist, Relieves the Severity of Streptozotocin–Nicotinamide-Induced Diabetes in Rats-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

ZB-16, a Novel GPR119 Agonist, Relieves the Severity of Streptozotocin–Nicotinamide-Induced Diabetes in Rats

Published:2017-07-07 Issue: Volume:8 Page:
ISSN:1664-2392
Container-title:Frontiers in Endocrinology
language:
Short-container-title:Front. Endocrinol.

Author:

Tyurenkov Ivan N.,Kurkin Denis V.,Bakulin Dmitry A.,Volotova Elena V.,Chafeev Mikhail A.,Smirnov Alexey V.,Morkovin Evgeny I.

Publisher

Frontiers Media SA

Subject

Endocrinology, Diabetes and Metabolism

Reference15 articles.

1. GIP and GLP-1, the two incretin hormones: similarities and differences;Seino;J Diabetes Investig,2010

2. An overview of new GLP-1 receptor agonists for type 2 diabetes;Tomlinson;Expert Opin Investig Drugs,2016

3. Discovery of 17 gliptins in 17-years of research for the treatment of type 2 diabetes: a synthetic overview;Kushwaha;Chem Biol Interface,2014

4. G protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: recent progress and prevailing challenges;Ritter;J Med Chem,2016

5. Discovery of ZB40-0016 – a novel GPR119 agonist for type 2 diabetes treatment;Chafeev,2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates;Expert Opinion on Investigational Drugs;2024-02-23

2. Impact of Vitamin D3 on Carbonyl-Oxidative Stress and Matrix Metalloproteinases after Acute Intracerebral Hemorrhage in Rats with Type 2 Diabetes Mellitus;Endocrine, Metabolic & Immune Disorders - Drug Targets;2023-09

3. Considerations for Permitted Daily Exposure Calculation for Contaminants in Medicinal Products Manufactured in Shared Facilities;The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation;2022-08-17

4. Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment;Pharmacological Research;2022-06

5. Novel and emerging therapeutic drug targets for management of type 2 Diabetes Mellitus;Obesity Medicine;2021-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3